Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.
Evaluate the effect of compounds on action potentials recorded from hiPSC-derived cardiomyocytes using conventional manual patch clamp methodology.
Spontaneous or evoked action potentials can be recorded and used to determine the effect of compounds on a range of action potential parameters. The recordings are stable for >30 minutes, which allows the cumulative application of multiple concentrations of each compound.
The manual patch clamp assay generates high fidelity recordings that allow the detection of even subtle changes to the action potential waveform. This helps to successfully discern between compounds with low, medium and high proarrhythmic risk profiles. For example, the figures below show mean data generated using 50 nM dofetilide, which reveals a significant prolongation of all measured APD values.
Figure 1. hiPSC-derived cardiomyocyte action potential screening.
Figure 2. Drug effects on hiPSC-derived cardiomyocyte responses.
Figure 3. Changes in hiPSC-derived cardiomyocyte beat stability.
Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.
Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50